Drug search by name

Teniposide Intravenous and Myelosuppression

Generic Name: teniposide
Dosage Forms: n.a.
Other Brand Names: Vumon

Result of checking the interaction of drug Teniposide Intravenous and disease Myelosuppression for safety when used together.

Check result:

Teniposide Intravenous <> Myelosuppression

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Teniposide induces severe myelosuppression at doses recommended to treat ALL. Leukopenia, primarily affecting neutrophils, thrombocytopenia, and anemia have been reported during teniposide therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Hemoglobin, white blood cell count and differential, and platelet count should be obtained before treatment initiation. Close clinical monitoring of hematopoietic function is recommended during treatment. If necessary, repeat bone marrow examination should be performed prior to the decision to continue therapy in the setting of severe myelosuppression. Patients with both Down syndrome and leukemia may be especially sensitive to myelosuppressive chemotherapy, therefore, initial dosing with teniposide should be reduced in these patients. It is suggested that the first course of teniposide should be given at half the usual dose.

References: